SCHEMBL4477441

SCHEMBL4477441

COc1c(C=Cc2ccccc2)c(C)n(-c2c(F)cccc2F)c(=O)c1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 6/20 0.41
MAPK14 Q16539 5/20 0.39
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35
TUBA1C Q9BQE3 1/20 0.35
TUBB6 Q9BUF5 1/20 0.35
TUBB2B Q9BVA1 1/20 0.35
TUBB1 Q9H4B7 1/20 0.35
LMNA P02545 2/20 0.35
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477435 1.00 NFE2L2 (0.41) NFE2L2MAPK14TUBB4ATUBBTUBA3C
SCHEMBL4466532 0.83 MAPK14 (0.39) MAPK14PDE4APDE4BPDE4CPDE4D
SCHEMBL4384658 0.81 MAPK14 (0.61) MAPK14
SCHEMBL4384661 0.81 MAPK14 (0.61) MAPK14
SCHEMBL4377030 0.68 MAPK14 (0.46) MAPK14LMNAPDE7ANPC1RAB9A
SCHEMBL4390400 0.66 MAPK14 (0.64) MAPK14
SCHEMBL4385117 0.65 MAPK14 (0.63) MAPK14
SCHEMBL5309943 0.65 NFE2L2 (0.40) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5309947 0.65 NFE2L2 (0.40) NFE2L2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4384354 0.63 MAPK14 (0.53) MAPK14PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 NFE2L2 2224/4885MAPK14 41/4885TUBB4A 1429/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 NFE2L2 1745/4885MAPK14 53/4885TUBB4A 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.